High grade prostate carcinoma C61
Conditions
Interventions
Group 1: Next generation sequencing (NGS) of an extended DNA repair gene panel of paraffin embedded tumor tissue at time of diagnosis (biopsy or prostatectomy).
At Initial presentation and at every p
Sponsors
Universitätsklinikum Heidelberg Nationales Centrum für Tumorerkrankungen (NCT) Medizinische Onkologie und Urologische Klinik
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: • Histological subtype: adenocarcinoma of the prostate without neuroendocrine differentiation • age at disease onset =50 years and/or • M1 (primary metastasized; every Gleason score, every T, every N, every M) and/or • Gleason Score 9 or 10 (every T, every M) and/or • Gleason Score 8 in combination with =pT3 or N1 or PSA =20 ng/ml and/or • early tumor recurrence or persistence after local therapy (Prostatectomy or Radiotherapy of the prostate) within =12 months and with high PSA doubling time of =3 months and/or • early development of castrations resistance of the prostate cancer under first line treatment with ADT alone or combination of ADT with Docetaxel or Abiraterone • no contraindication for approved treatments • ECOG: 0-1 • availability of tumor tissue in good quality for DNA sequencing • Complete clinical documentation (PSA at diagnosis, histology, Gleason Score, TNM-Score, course of treatment, course of PSA, radiological reports of all scans since the time of diagnosis
Exclusion criteria
Exclusion criteria: • pre-existing psychiatric disorder • other active malignant diseases • non legally competent or incapacitated patients • patients, who refuse to undergo systemic treatments
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression of disease | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival | — |
Countries
Germany
Contacts
Public ContactCathleen Nientiedt
Universitätsklinikum Heidelberg Nationales Centrum für Tumorerkrankungen (NCT) Medizinische Onkologie
Outcome results
None listed